European Commission approves Benlysta for adult patients with active lupus nephritis pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Pathline Expands Medical Team, Appoints Three New Physicians
May 3, 2021 GMT
RAMSEY, N.J. (BUSINESS WIRE) May 3, 2021
Pathline, a leading provider of specialized anatomic pathology services, has expanded its team with a new Chief Medical Officer, Director of Hematopathology and Molecular Pathology and Senior Pathologist. The recently appointed physicians include:
Gregory S. Henderson, M.D., Ph.D., F.C.A.P., F.A.S.C.P. - Chief Medical Officer
Bevan Tandon, M.D. - Director of Hematopathology and Molecular Pathology
Douglas Charney, M.D. - Senior Pathologist
In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes asnjournals.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asnjournals.org Daily Mail and Mail on Sunday newspapers.
FDA approves GSK s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
Approval builds on nearly 10 years of experience in lupus
News provided by
Share this article
Share this article
LONDON, Dec. 17, 2020 /PRNewswire/ GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus (SLE), the most common form of lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant. The approval extends the current indication in the US to include both SLE and LN for both the intravenous and subcutaneous formulations.